Quantcast
Last updated on April 18, 2014 at 11:01 EDT

Latest Unigene Laboratories Stories

2012-04-03 02:27:43

BOONTON, N.J., April 3, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics today announced Cara Therapeutics, Inc. completed its successful, first-in-man Phase 1 clinical trial using Unigene's oral formulation of Cara's peptide-based, peripherally-restricted kappa opioid receptor agonist, CR845. The trial was a single-center, double-blind, placebo-controlled study to evaluate the...

2012-04-02 02:29:04

BOONTON, N.J., April 2, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics today announced the appointment of Jack Wyszomierski to its Board of Directors. From 2004 until his retirement in 2009, Mr. Wyszomierski was the Executive Vice President and Chief Financial Officer of VWR International, LLC, a supplier of laboratory supplies, equipment and supply chain solutions to the global...

2012-03-29 02:26:37

BOONTON, N.J., March 29, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, announced today that David Moskowitz, Chief Financial Officer, will present a corporate overview at the 11th Annual Needham Healthcare Conference 2012 in New York, NY. Mr. Moskowtiz's presentation is scheduled to begin at 2:40 p.m. ET on Wednesday, April 4, 2012. A live webcast of the presentation will be...

2012-03-22 02:25:19

BOONTON, N.J., March 22, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today reported that the U.S. Supreme Court denied Apotex's Petition for a Writ of Certiorari on March 19, 2012, in Apotex, Inc., et al. v. Unigene Laboratories, Inc., et al., Supreme Court Docket No. 11-879. Thus, the validity of Unigene's U.S. patent on Fortical® has been confirmed by the District...

2012-03-21 02:24:24

PHILADELPHIA, March 21, 2012 /PRNewswire/ -- Tarsa Therapeutics today announced it has entered into a commercial supply agreement with QS Pharma for the bulk manufacture of its OSTORA(TM) oral recombinant salmon calcitonin tablet. The OSTORA tablets, which will be manufactured in QS Pharma's state-of-the-art facility in Pennsylvania, will be used for product launch and commercial sale. This new agreement builds on the continuing collaboration between Tarsa and QS Pharma that began with an...

2012-03-16 08:50:41

PHILADELPHIA, March 16, 2012 /PRNewswire/ -- Tarsa Therapeutics, Inc. today announced completion of a $28 million Series B equity financing led by new investor Foresite Capital. James Tananbaum, MD, Foresite's founder and CEO, is joining Tarsa's Board of Directors. Tarsa's existing venture capital investors--Novo A/S, MVM Life Science Partners and Quaker Partners--all participated in the new financing round. Following positive Phase III results and a successful pre-NDA meeting with the...

2012-03-15 06:42:00

BOONTON, N.J., March 15, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), today announced the appointment of David Moskowitz, RPh, MBA, to the position of Chief Financial Officer. In this newly created position, Mr. Moskowitz will serve as a member of the company's executive leadership team and lead the strategic direction of Unigene's financial and capital markets activities. Mr. Moskowitz joins Unigene after spending the previous 13 years as a top-rated equity research...

2012-03-08 06:45:00

BOONTON, N.J., March 8, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), today announced financial results for the fourth quarter and full-year ended December 31, 2011. The Company highlighted key corporate accomplishments in 2011 and outlined its anticipated milestones for 2012. Fourth Quarter and Full-Year 2011 Financial Summary Unigene announced positive net income of $4.4 million or $0.05 per share for the three months ended December 31, 2011 compared to a net loss...

2012-03-05 07:01:00

BOONTON, N.J., March 5, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), today announced that the Company signed a Clinical Manufacturing Services Agreement with Stealth Peptides Inc. (Stealth). Unigene will use its validated, proprietary Peptelligence(TM) platform as part of the agreement to support Phase 1 clinical plans for one of Stealth's investigational drug candidates. Stealth's Phase 1 clinical study is expected to begin later this year. Stealth recently commenced an...

2012-03-01 07:02:00

BOONTON, N.J., March 1, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company's senior management team will host a conference call and live audio webcast on Thursday, March 8, 2012 at 11 a.m. ET to discuss fourth quarter and full-year 2011 financial results. Interested participants and investors may access the conference call at 11 a.m. ET by dialing...